Increased NF-κB expression in human patients and the role of non-canonical NF-κB pathway in CD and UC pathogenesis as well as the role of non-canonical NF-κB signaling as a therapeutic target and biomarker in IBD patients suggest its importance in clinical settings [86,87]. The gene discussed is NFKB1; the disease is inflammatory bowel disease.